Akizawa T - Search Results

1

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.

Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Akizawa T, et al. Ther Apher Dial. 2021 Oct;25(5):575-585. doi: 10.1111/1744-9987.13609. Epub 2020 Dec 15. Ther Apher Dial. 2021. PMID: 33200512 Free PMC article. Clinical Trial.

2

2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.

Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M; Japanese Society for Dialysis Therapy. Gejyo F, et al. Among authors: akizawa t. Ther Apher Dial. 2004 Dec;8(6):443-59. doi: 10.1111/j.1774-9987.2004.00199.x. Ther Apher Dial. 2004. PMID: 15663544

3

Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients.

Akizawa T, Koshikawa S, Iwasaki M; KRN321 A08 Study Group. Akizawa T, et al. Ther Apher Dial. 2007 Jun;11(3):220-6. doi: 10.1111/j.1744-9987.2007.00474.x. Ther Apher Dial. 2007. PMID: 17498005 Clinical Trial.

4

Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.

Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S; KRN321 A09 Study Group. Hiramatsu M, et al. Among authors: akizawa t. Ther Apher Dial. 2008 Feb;12(1):19-27. doi: 10.1111/j.1744-9987.2007.00525.x. Ther Apher Dial. 2008. PMID: 18257808 Clinical Trial.

5

Quality of life improvements in dialysis patients receiving darbepoetin alfa.

Fukuhara S, Akizawa T, Morita S, Koshikawa S; KRN321 A08 Study Group. Fukuhara S, et al. Among authors: akizawa t. Ther Apher Dial. 2008 Feb;12(1):72-7. doi: 10.1111/j.1744-9987.2007.00544.x. Ther Apher Dial. 2008. PMID: 18257816 Clinical Trial.

6

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.

Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S; KRN1493 Study Group. Akiba T, et al. Among authors: akizawa t. Ther Apher Dial. 2008 Apr;12(2):117-25. doi: 10.1111/j.1744-9987.2008.00556.x. Ther Apher Dial. 2008. PMID: 18387159 Clinical Trial.

7

Clinical study of cinacalcet in Japan.

Akizawa T, Koshikawa S. Akizawa T, et al. Ther Apher Dial. 2008 Oct;12 Suppl 1:S13-5. doi: 10.1111/j.1744-9987.2008.00625.x. Ther Apher Dial. 2008. PMID: 19032520

8

Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.

Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A; K Study Group. Yajima A, et al. Among authors: akizawa t. Ther Apher Dial. 2008 Oct;12 Suppl 1:S38-43. doi: 10.1111/j.1744-9987.2008.00630.x. Ther Apher Dial. 2008. PMID: 19032526

9

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. Tsubakihara Y, et al. Among authors: akizawa t. Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x. Ther Apher Dial. 2010. PMID: 20609178

10

Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.

Ashikaga E, Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Matsumoto K, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T. Ashikaga E, et al. Among authors: akizawa t. Ther Apher Dial. 2010 Jun;14(3):315-22. doi: 10.1111/j.1744-9987.2009.00796.x. Ther Apher Dial. 2010. PMID: 20609185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

590 results

Search Page

Filters